Capricor Therapeutics Cleared To Begin Phase II Portion Of ALLSTAR Clinical Trial With CAP-1002 In Patients Following Heart Attack
12/17/2013 9:18:58 AM
LOS ANGELES--(BUSINESS WIRE)--Capricor Therapeutics, Inc. (OTCBB: NLTXD) today announced that it has received notification from the National Heart Lung and Blood Institute (NHLBI) Gene and Cell Therapy (GST) Data Safety Monitoring Board (DSMB) that the 14-patient Phase I portion of the Company’s ALLSTAR Phase I/II clinical trial has met its safety endpoints and that the Company is now cleared to begin the Phase II portion of the ALLSTAR clinical trial.
Help employers find you! Check out all the jobs and post your resume.
comments powered by